Osteoporosis News

Winteam Pharmaceutical Group Ltd. , a maker of drugs in China , will buy a producer of traditional Chinese medicine for as much as HK$3.05 billion to gain products including an osteoporosis treatment.

About 10 million Americans have the condition that occurs when bones become weak, brittle and likely to break.

The National Institutes of Health awarded $475,076 to OsteoGeneX Inc., a Kansas City, Kan., private pharmaceutical company focused on developing a treatment for osteoporosis.

A new combination drug therapy for osteoporosis appears to increase bone density more effectively than any treatment now on the market, according to the results of a small clinical trial.

Using a combination of the drugs, already available on the NHS, resulted in an increase in bone density of up to 5 per cent in just a year, they found.

Each year the number of fractures related to osteoporosis in women is greater than the combined number of heart attacks, strokes, and cases of breast cancer.

The drugmakers Actavis Inc. and Warner Chilcott PLC say they are holding early discussions about a possible combination of the two companies.

The single, easiest way to keep track of all the stocks that matter... Your own personalized stock watchlist! It's a 100% FREE Motley Fool service... ) will release its latest quarterly results.

Mutations in a gene involved in bone development appear to cause certain severe forms of bone loss, a finding that could lead to new therapies for the common bone-thinning disorder osteoporosis, researchers report.

Satellite radio's "ReachMD," and the "Balancing Act" on Lifetime Television Focus on Breakthrough Treatment for Osteoporosis and Patients Who Have Difficulty Swallowing Pills.

I read your column and thought I would share my experience of using the drug Fosamax .

Most importantly, the 'gold-standard' bisphosphonates will lose patent protection by end-of-year 2013, flooding the marketplace with less expensive generic versions of these physician-preferred medications.

GlobalData has released its new PharmaPoint Drug Evaluation report, "Recalbon/Bonoteo - Forecast and Market Analysis to 2022". Despite its maturity, the osteoporosis market is expected to undergo substantial change between 2012 and 2022.

GlobalData has released its new PharmaPoint Drug Evaluation report, "Reclast - Forecast and Market Analysis to 2022". Despite its maturity, the osteoporosis market is expected to undergo substantial change between 2012 and 2022.

Most importantly, the 'gold-standard' bisphosphonates will lose patent protection by end-of-year 2013, flooding the marketplace with less expensive generic versions of these physician-preferred medications.

The Doctors share 4 ways to improve bone health, r...: The Doctors share 4 ways to improve bone health, reduce fractures.

According to the National Osteoporosis Foundation , about 10 million Americans live with osteoporosis, while an estimated 34 million are at risk for the disease.

More than 700,000 people suffer spinal fractures due to osteoporosis each year - double the number of people who experience hip fractures, according to the International Osteoporosis Foundation.

We continue to view Bahrain as one of the more attractive in the Middle East and Africa region, mostly on account of the relatively high per capita spending, developed healthcare infrastructure and a solid regulatory background.

GlobalData has released its new PharmaPoint Drug Evaluation report, "Actonel - Forecast and Market Analysis to 2022". Despite its maturity, the osteoporosis market is expected to undergo substantial change between 2012 and 2022.